Background
==========

This case outlines the clinical approach to identifying the etiology of pulmonary edema in the setting of hypothyroidism. Pulmonary edema associated with hypothyroidism has been explained by the loss of inotropic and chronotropic effects of the thyroid hormone in the heart (i.e., cardiogenic pulmonary edema) [@bib1]. However, in this report, we demonstrate a case of hypothyroidism associated with non-cardiogenic pulmonary edema explained by a different mechanism. We believe that this case exemplifies the importance of keeping an open mind and looking for a pathology that would explain the whole clinical scenario.

Case presentation
=================

A 42-year-old female with a past medical history of mild intermittent asthma and hypothyroidism (status after radioactive iodine treatment for Graves' disease 15 years ago) presented to the emergency department (ED) with progressive shortness of breath for 1 week. She had been doing well and not seen her primary care physician for about 5 years. A week before her ED presentation, she developed a sore throat and dry cough for 2 days. Shortly after, she started to have exertional dyspnea, which progressed gradually from New York Heart Association (NYHA) classes II--IV over the course of 4 days. This was associated with significant orthopnea causing insomnia the night before her ED presentation. She also noticed swelling of both lower limbs and hands.

Review of systems was remarkable for lethargy, cold intolerance, constipation, menorrhagia for 5 years, nocturnal snoring, frequent awakening, and daytime fatigue for about 4 months. When asked about compliance, the patient insisted that she had been taking levothyroxine ([l]{.smallcaps}-T~4~) everyday with her breakfast, which includes a cup of coffee.

On physical examination, our patient was sitting upright and in moderate respiratory distress. She was afebrile with a blood pressure of 113/65 mmHg, heart rate of 61/min, respiratory rate of 22/min, oxygen saturation of 98% on room air, and BMI of 32. There was no pulsus paradoxus. Heart sounds were regular with no extra-heart sound, murmur, or gallop. Neck circumference was 18 inches with no jugular venous distension (JVD). She had bilateral inspiratory basal crackles with no rhonchi on respiratory examination and bilateral +1 pitting edema in her lower extremities.

Which of the following is the most likely explanation for the shortness of breath in this patient?

Asthma exacerbation.Pulmonary edema.Pneumonia.Pulmonary embolism (PE).

Despite the past medical history of asthma in our patient, the absence of rhonchi and the presence of bilateral basal inspiratory crackles make the diagnosis of acute asthma exacerbation less likely. The history of significant orthopnea and findings of peripheral pitting edema and bilateral lung crackles on examination favor the diagnosis of pulmonary edema. Pneumonia is less likely in the absence of fever and sputum production. It is also very unlikely that our patient had a PE, given that she was not hypoxic or tachycardic and had no risk factors for PE. Her calculated Wells' score of 0 makes PE very unlikely.

Given the timeline of the symptoms and the acute presentation of orthopnea a few days after upper respiratory tract infection, our most likely diagnosis was cardiogenic pulmonary edema possibly secondary to viral myocarditis and non-ischemic cardiomyopathy.

Investigation
=============

Chest X-ray (CXR) showed pulmonary edema ([Fig. 1](#fig1){ref-type="fig"}).

![Chest X-ray showing pulmonary edema.](edmcr-2015-150014-g001){#fig1}

Which of the following tests would you order next?

D-dimer.Brain natriuretic peptide.Polysomnography.Angiocardiography.

The plasma level of BNP can be measured in the ED and utilized as a simple and reliable biomarker to differentiate cardiogenic pulmonary edema from non-cardiogenic pulmonary edema [@bib2]. Our patient had a BNP level of 16 pg/ml making congestive heart failure and cardiogenic pulmonary edema very unlikely. The results of her remaining blood tests are outlined in [Table 1](#tbl1){ref-type="table"} including a thyrotropin (TSH) level of 43.72 mIU/l and T~4~\<0.2 mIU/l.

###### 

Results of the initial blood tests

  **Test**                                          **Result**
  ------------------------------------------------- -------------------------
  WBC                                               8.2 (×10^3^)
  Hemoglobin                                        8.7 (g/dl)
  Mean corpuscular volume (MCV)                     80 (fl)
  Platelets                                         427
  BUN                                               12 (mg/dl)
  Creatinine                                        1.40 (mg/dl)
  eGFR                                              57.83 (ml/min per 1.73)
  TSH                                               43.72 (mIU/l)
  Free T~4~                                         \<0.20 (ng/dl)
  B-type natriuretic peptide (BNP)                  16 (pg/ml)
  Cholesterol                                       401 (mg/dl)
  LDL                                               332 (mg/dl)
  HDL                                               55 (mg/dl)
  Triglyceride                                      70 (mg/dl)
  Anti-neutrophil antibodies (ANA)                  Positive (homogeneous)
  Anti-double-stranded DNA antibody (anti ds-DNA)   9 (IU/ml)
  Complement 3                                      125 (mg/dl)
  Complement 4                                      28 (mg/dl)

Electrocardiogram (EKG) showed sinus bradycardia (heart rate (HR)=55/min) with a first-degree heart block and no acute ST or T wave changes. Echocardiogram showed an ejection fraction of 60--65% with normal diastolic function and mildly elevated right ventricular systolic pressure at 44.7 mmHg. Computed tomography of the chest showed ground-glass densities predominant in the lung-dependent regions compatible with pulmonary edema and no PE ([Fig. 2](#fig2){ref-type="fig"}).

![Computed tomography of the chest showing ground-glass densities compatible with pulmonary edema.](edmcr-2015-150014-g002){#fig2}

Treatment
=========

At this stage, our working diagnosis changed from cardiogenic to non-cardiogenic pulmonary edema. The patient was started on furosemide 40 mg intravenously daily for 2 days and the [l]{.smallcaps}-T~4~ dose was increased from 175 to 225 μg. The patient was advised to take [l]{.smallcaps}-T~4~ first in the morning on an empty stomach.

Outcome and follow-up
=====================

Over the course of 2 weeks, the shortness of breath and orthopnea subsided gradually and by the fourth night, the patient was able to sleep on one pillow with no orthopnea. Two weeks later, her shortness of breath, orthopnea, and lower extremity edema resolved and furosemide was discontinued. Four weeks later, her TSH level dropped to 0.37 mIU/l. She declined the sleep study and wanted to be treated only for hypothyroidism.

Discussion
==========

Identifying the underlying etiology of the first episode of pulmonary edema can sometimes be challenging as all causes of pulmonary edema share the same clinical features to some extent. The first step in approaching pulmonary edema is to differentiate cardiac etiologies from non-cardiac etiologies. Clinical features that point toward cardiogenic pulmonary edema include history of acute coronary syndrome or congestive heart failure and the finding of S3, JVD, or peripheral pitting edema on physical examination. Other features of cardiogenic pulmonary edema include elevated cardiac enzymes and enlarged cardiac silhouette or the presence of Kerley B lines in CXR [@bib3]. In contrast, non-cardiac etiologies of pulmonary edema should be suspected in patients with ongoing pulmonary or non-pulmonary infection and sleep apnea syndrome (SAS), those at the risk of aspiration pneumonia or inhalation injury, and after multiple blood transfusions [@bib3]. The gold standard test to differentiate cardiogenic pulmonary edema from non-cardiogenic pulmonary edema is pulmonary artery catheterization [@bib4]. However, this invasive procedure is rarely used in clinical practice except for patients who are in shock with pulmonary edema of unclear etiology. The production of BNP by the cardiac ventricles in response to ventricular expansion makes it a good biomarker to differentiate between cardiogenic and non-cardiogenic pulmonary edema. BNP level \<100 pg/ml has a negative predictive value of \>90%, while BNP level of \>500 pg/ml has a positive predictive value of \>90% [@bib5].

Severe hypothyroidism can lead to congestive heart failure and cardiogenic pulmonary edema through the loss of inotropic and chronotropic effects of thyroid hormone [@bib1]. However, on rare occasions such as our patient\'s case, severe hypothyroidism can indirectly lead to non-cardiogenic pulmonary edema. SAS is believed to be the missing link between hypothyroidism and non-cardiogenic pulmonary edema in most of these cases [@bib6]. The association between hypothyroidism and central or obstructive SAS has been described in the literature [@bib7]. Proposed mechanisms of this association include deposition of mucoprotein in the upper airway causing airway obstruction and obstructive SAS [@bib7]. More interestingly, thyroid replacement was found to be effective in treating both hypothyroidism and SAS in reported cases [@bib8] [@bib9]. Another explanation of pulmonary edema is that capillary permeability increases in state of hypothyroidism, which subsequently results in the leakage of plasma proteins [@bib10].
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